Results 151 to 160 of about 148,764 (203)
Some of the next articles are maybe not open access.
Mammalian dihydropyrimidine dehydrogenase
Archives of Biochemistry and Biophysics, 2021Dihydropyrimidine dehydrogenase (DPD) catalyzes the two-electron reduction of pyrimidine bases uracil and thymine as the first step in pyrimidine catabolism. The enzyme achieves this simple chemistry using a complex cofactor set including two flavins and four Fe4S4 centers.
Dariush C. Forouzesh, Graham R. Moran
openaire +2 more sources
[Dihydropyrimidine dehydrogenase deficiency].
Ryoikibetsu shokogun shirizu, 1998Dihydropyrimidine dehydrogenase (DPD) deficiency (McKusick 274270) is a, clinically heterogeneous, autosomal recessive disease. DPD (EC 1.3.1.2) catalyzes the first and rate-limiting step in the catabolism of uracil, thymine and the analogue 5-fluorouracil.
M, Kouwaki, Y, Wada
openaire +3 more sources
Dihydropyrimidine dehydrogenase deficiency — A further case
Journal of Inherited Metabolic Disease, 1985Dihydropyrimidine dehydrogenase (EC 1.3.1.2.) deficiency has recently been described in two separate reports of four patients, all of whom excreted large quantities of thymine and uracil in the urine. Bakkeren et al. (1984) described a girl who developed grand-mal epilepsy at 3 years of age, and had microcephaly, but normal intelligence. Berger et al. (
WILCKEN, B +4 more
openaire +3 more sources
A new case of dihydropyrimidine dehydrogenase deficiency
Journal of Inherited Metabolic Disease, 1989SummaryWe present the clinical and biochemical features of a boy with dihydropyrimidine dehydrogenase deficiency, which seem to underline a disease entity of developmental retardation, epilepsy and muscular hypertonia.
BROCKSTEDT, M +4 more
openaire +3 more sources
5-Fluorouracil and dihydropyrimidine dehydrogenase
International Journal of Clinical Oncology, 2003Dihydropyrimidine dehydrogenase (DPD) is a rate-limiting enzyme of (fluorinated) pyrimidine degradation that plays a significant role in the pharmacokinetics of 5-fluorouracil (5-FU). In addition, a catabolite of 5-FU induces a certain toxicity, and the sensitivity of 5-FU is determined by DPD activity in tumors. DPD is thus important clinically. Drugs
openaire +3 more sources
Dihydropyrimidine Dehydrogenase Activity in a Korean Population
Therapeutic Drug Monitoring, 1999Dihydropyrimidine dehydrogenase (DPD) is the major metabolic enzyme in the catabolism of 5-fluorouracil, and the activity in normal tissues shows a wide variation among individuals. Recent studies demonstrate the relevance of DPD in the pharmacokinetics, toxicity, and antitumor efficacy of 5-fluorouracil.
D R, Sohn, M S, Cho, P J, Chung
openaire +2 more sources
Dihydropyrimidine dehydrogenase deficiency presenting at birth
Journal of Inherited Metabolic Disease, 2005SummaryDihydropyrimidine dehydrogenase (DPD) deficiency (McKusick 274270) is a clinically heterogeneous autosomal recessive disorder of pyrimidine metabolism. DPD is the enzyme that catalyses the first and the rate‐limiting step in the catabolism of uracil, thymine and the analogue 5‐fluorouracil. To date, more than 30 patients have been diagnosed with
Al-Sanna'a, N. A. +4 more
openaire +3 more sources
Dihydropyrimidine dehydrogenase activity in cancer patients
European Journal of Cancer, 1993Dihydropyrimidine dehydrogenase (DPD) is the major catabolic enzyme of pyrimidines and fluoropyrimidines. The clinical course of 2 patients with suspected DPD deficiency is described. Both patients had significantly delayed clearance of fluorouracil (5-FU), elevated plasma uracil concentrations, and subsequent lethal toxicity.
R A, Fleming +8 more
openaire +2 more sources
Dihydropyrimidine dehydrogenase deficiency in an Indian population
Cancer Chemotherapy and Pharmacology, 2006Dihydropyrimidine dehydrogenase (DPD) deficiency is prevalent in 3-5% of the Caucasian population; however, the frequency of this pharmacogenetic syndrome in the Indian population and other racial and ethnic groups remains to be elucidated.We describe an Indian patient who presented to clinic for the treatment of gastric adenocarcinoma with 5 ...
Muhammad Wasif, Saif +4 more
openaire +2 more sources
Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase
Expert Opinion on Investigational Drugs, 2000One of the most widely used drugs in cancer chemotherapy is 5-fluorouracil (5-FU). 5-FU is optimally delivered via continuous iv. infusion, which is both cumbersome and expensive. Prolonged oral dosing of 5-FU could mimic continuous infusion with less inconvenience and cost.
R L, Schilsky, H L, Kindler
openaire +2 more sources